Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Iradimed (IRMD) Cash & Equivalents (2016 - 2026)

Iradimed has reported Cash & Equivalents over the past 14 years, most recently at $56.4 million for Q1 2026.

  • Quarterly Cash & Equivalents rose 12.01% to $56.4 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $56.4 million through Mar 2026, up 12.01% year-over-year, with the annual reading at $51.2 million for FY2025, 2.06% down from the prior year.
  • Cash & Equivalents was $56.4 million for Q1 2026 at Iradimed, up from $51.2 million in the prior quarter.
  • Over five years, Cash & Equivalents peaked at $58.0 million in Q4 2022 and troughed at $42.8 million in Q1 2023.
  • The 5-year median for Cash & Equivalents is $51.2 million (2025), against an average of $51.0 million.
  • Year-over-year, Cash & Equivalents dropped 15.91% in 2023 and then rose 12.01% in 2026.
  • A 5-year view of Cash & Equivalents shows it stood at $58.0 million in 2022, then decreased by 14.15% to $49.8 million in 2023, then increased by 4.97% to $52.2 million in 2024, then dropped by 2.06% to $51.2 million in 2025, then rose by 10.19% to $56.4 million in 2026.
  • Per Business Quant, the three most recent readings for IRMD's Cash & Equivalents are $56.4 million (Q1 2026), $51.2 million (Q4 2025), and $56.5 million (Q3 2025).